Latest From Bluepharma SA
Novartis will invest in the Calgary-based Parvus and collaborate on a Navacim candidate for type 1 diabetes. Japan's Sawai moves into the US market by acquiring Upsher-Smith's generics business, while Denovo acquires a suspended depression candidate from AMRI for its personalized development approach.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2016.
- Nanotechnology, Chips, etc.
- Contract Research, Toxicology Testing-CRO
- Drug Delivery
- Generic Drugs
- Therapeutic Areas
- Infectious & Viral Diseases
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Bluepharma SA
- Senior Management
Paulo Barradas Rebelo , CEO
Catarina Xavier , CFO
Claudia Silva , CSO
Andre Freitas , Head, Bus. Dev.
Maria Isolina Mesquita , VP, Operations
Sergio Simoes , VP, Bus. & Product Dev.
Emilia Alcoforado , Head, Regulatory Affairs
- Contact Info
Phone: 239 800 300
Sao Martinho do Bispo
Coimbra , 3045-016
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.